A federal judge rejected LegitScript’s motion to dismiss the case, which alleges efforts to hide low-cost prescription options from consumers.
Jul 12, 2022
Premium
Image
Members of the Oregon Prescription Drug Affordability Board meet for the first time on Thursday. The board will study high drug prices and recommend solutions./Screenshot by Ben Botkin
As insulin-makers face long-standing complaints of price-gouging, California is diving into the prescription drug business, attempting to produce its own brand of generic insulin and sell it at below-market prices to people with diabetes.
A Pfizer win in a lawsuit against the federal government could cost taxpayers billions of dollars and erase an important control on pharma marketing after decades of regulatory erosion and soaring drug prices, say health policy analysts.
But they face drug industry opposition as they consider bills to make generic drugs more available, limit out-of-pocket insulin costs and set price limits on expensive drugs.
The state released its latest drug transparency data, which shows that Humira, used for rheumatoid arthritis, racked up $81 million in sales over the past year.